Kim Edmonds
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Treatments and Studies
-
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
Papers in
- Oncology 9
- Cutaneous Melanoma Detection and Management 5
- Cancer Immunotherapy and Biomarkers 4
- COVID-19 and healthcare impacts 2
-
- Melanoma and MAPK Pathways 4
- Renal and related cancers 2
- Co-authors
- Martin Gore (6 shared papers)James Larkin (10 shared papers)Julia Newton‐Bishop (2 shared papers)Louise Fearfield (2 shared papers)R. K. Sinha (1 shared paper)Tim Eisen (1 shared paper)Michelle Harrison (1 shared paper)Susan Hoare (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Annals of Oncology (2 papers)Clinical Cancer Research (1 paper)Melanoma Research (1 paper)Expert Opinion on Drug Safety (1 paper)
- Partner nations
- United KingdomNetherlandsGreece
In The Last Decade
Kim Edmonds
15 papers receiving 564 citations
Peers
Comparison fields: 5 of 78
- Oncology 257
- Immunology 117
- Cancer Research 62
- Molecular Biology 192
- Pharmacology 22
Countries citing papers authored by Kim Edmonds
This map shows the geographic impact of Kim Edmonds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Edmonds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Edmonds more than expected).
Fields of papers citing papers by Kim Edmonds
This network shows the impact of papers produced by Kim Edmonds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Edmonds. The network helps show where Kim Edmonds may publish in the future.
Co-authors
The 25 scholars most cited alongside Kim Edmonds, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 205 | |
| 2 | 1994 | 110 | |
| 3 | 2012 | 87 | |
| 4 | 2019 | 52 | |
| 5 | 2011 | 34 | |
| 6 | 2010 | 33 | |
| 7 | 2013 | 19 | |
| 8 | 2022 | 12 | |
| 9 | 2021 | 10 | |
| 10 | 2015 | 8 | |
| 11 | 2010 | 3 | |
| 12 | 2017 | 2 | |
| 13 | 2012 | 1 | |
| 14 | 2012 | 1 | |
| 15 | 2011 | 1 | |
| 16 | CAPTURE: Cancer and COVID-19 antiviral immune monitoring study | 2020 | 0 |
About Kim Edmonds
Kim Edmonds is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Infectious Diseases and Nephrology, having authored 16 papers that have together received 578 indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (5 papers), Renal cell carcinoma treatment (4 papers), Melanoma and MAPK Pathways (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), COVID-19 and healthcare impacts (2 papers), Renal Diseases and Glomerulopathies (2 papers), Renal and related cancers (2 papers) and Pharmacogenetics and Drug Metabolism (1 paper). The work is most often cited by research in Oncology (257 citations), Immunology (117 citations), Cancer Research (62 citations), Molecular Biology (192 citations) and Pharmacology (22 citations). Kim Edmonds has collaborated with scholars based in United Kingdom, Netherlands and Greece. Frequent co-authors include Martin Gore, James Larkin, Julia Newton‐Bishop, Louise Fearfield, R. K. Sinha, Tim Eisen, Michelle Harrison, Susan Hoare, Mark DeWitte and Frances R. Balkwill. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Melanoma Research and Expert Opinion on Drug Safety.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.